key: cord-0304534-1blu1lid authors: Moin, Syed M.; Boyington, Jeffrey C.; Boyoglu-Barnum, Seyhan; Gillespie, Rebecca A.; Cerutti, Gabriele; Cheung, Crystal Sao-Fong; Cagigi, Alberto; Gallagher, John R.; Brand, Joshua; Prabhakaran, Madhu; Tsybovsky, Yaroslav; Stephens, Tyler; Fisher, Brian E.; Creanga, Adrian; Ataca, Sila; Rawi, Reda; Corbett, Kizzmekia S.; Crank, Michelle C.; Gorman, Jason; McDermott, Adrian B.; Harris, Audray K.; Zhou, Tongqing; Kwong, Peter D.; Shapiro, Lawrence; Mascola, John R.; Graham, Barney S.; Kanekiyo, Masaru title: Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses date: 2022-02-12 journal: bioRxiv DOI: 10.1101/2022.02.11.480115 sha: 99e23f032bdc3a4d04d369482a2dcdc9fb940a24 doc_id: 304534 cord_uid: 1blu1lid Current influenza vaccines predominantly induce immunity to the hypervariable viral hemagglutinin (HA) head, requiring frequent vaccine reformulation. Conversely, antigenic sites on the conserved HA stem are subdominant and harbor a supersite which is targeted by broadly neutralizing antibodies (bnAbs), making it a prime target for universal vaccines. Here, we show that co-immunization of two stem immunogens derived from influenza A group 1 and 2 HAs elicits cross-group protective immunity and neutralizing antibody responses in mice, ferrets, and nonhuman primates (NHPs). Immunized mice were protected from multiple group 1 and 2 viruses, and all animal models showed broad serum neutralizing activity. A bnAb isolated from an immunized NHP broadly neutralized and conferred protection from viruses including H5N1 and H7N9. Genetic and structural analyses revealed a remarkable convergent evolution between macaque and human bnAbs, illustrating the biophysical constraints for acquiring immunoglobulins with cross-group specificity. Co-immunization of stem immunogens elicits not only group-specific protective immunity, but also cross-group bnAb responses, and represents a step towards broadly protective influenza vaccines. from influenza A group 1 and 2 HAs elicits cross-group protective immunity and neutralizing antibody responses in mice, ferrets, and nonhuman primates (NHPs). Immunized mice were protected from multiple group 1 and 2 viruses, and all animal models showed broad serum neutralizing activity. A bnAb isolated from an immunized NHP broadly neutralized and conferred protection from viruses including H5N1 and H7N9. Genetic and structural analyses revealed a remarkable convergent evolution between macaque and 35 human bnAbs, illustrating the biophysical constraints for acquiring immunoglobulins with cross-group specificity. Co-immunization of stem immunogens elicits not only group-specific protective immunity, but also cross-group bnAb responses, and represents a step towards broadly protective influenza vaccines. Influenza virus causes a substantial global health and economic burden despite the availability of 40 commercial vaccines. Moreover, it poses a unique biological challenge by evading host immune responses through its genetic plasticity leading to antigenic variation, making the virus a constantly moving target. Current influenza vaccines provide narrow-spectrum protection against antigenically closely matched strains, resulting in inconsistent 10-60% vaccine efficacy against symptomatic disease in humans 1 . This also necessitates annual update of the vaccine strains in order to match the predicted circulating viruses. 45 Furthermore, these vaccines are not expected to confer meaningful protection against zoonotic virus strains from animal reservoirs that cause sporadic outbreaks in humans and have pandemic potential. Current influenza vaccines target the most abundant influenza viral glycoprotein, hemagglutinin (HA). HA is a homotrimeric class I fusion protein which densely decorates virions along with another glycoprotein neuraminidase (NA). To date, 18 phylogenetically different HA subtypes and 11 NA subtypes have been 50 identified in influenza A viruses. These 18 HA subtypes are categorized in 2 distinct groups (group 1 and 2). The HA glycoprotein is expressed as a precursor HA0 which is subsequently cleaved by cellular proteases into HA1 and HA2 (ref. 2 ). This cleavage is required for virus infectivity and HA1 and HA2 are covalently linked by disulfide bonds 3 . HA has two functionally and structurally distinct regions, head and stem, that mediate host cell attachment and viral membrane fusion processes, respectively. The hypervariable head 55 region contains antigenic sites that are highly neutralization sensitive and immunodominant, whereas the stem region is considerably more conserved within each group and recognized by broadly neutralizing antibodies (bnAbs) that are typically less potent than head-directed monoclonal antibodies (mAbs). These antibodies also utilize Fc-mediated effector functions such as antibody dependent cell-mediated cytotoxicity to broaden protection against diverse influenza strains 4-6 . Multiple broadly neutralizing monoclonal 60 antibodies have been isolated from humans that are capable of neutralizing different group 1 or group 2 subtypes or viruses from both groups 7, 8 . Hence, one major strategy for universal influenza vaccine efforts has been to focus on the HA stem domain to achieve broad protection against seasonal and pandemic influenza viruses without yearly reformulation. We and others have shown previously that rationallydesigned immunogens based on the HA stem elicit broadly cross-reactive antibody responses and confer 65 heterosubtypic protection against H5N1 infection in animal models [9] [10] [11] [12] [13] . However, cross-group protection against heterosubtypic group 2 viruses has not been reported for HA stem-based immunogens. Recently, parallel approaches have been pursued to generate group 2 HA stem immunogens based on H3 and H7 (refs. 14, 15 ). Although these stem immunogens elicited intra-group cross-reactive antibody responses and homotypic protective immunity in small animals, the induction of bnAb responses that resemble human 70 bnAbs has not been demonstrated. The group 2 H3 and H7 HA stem displayed on ferritin nanoparticles were shown to activate B cells expressing B cell receptors of unmutated common ancestors (UCAs) for human cross-group bnAbs representing two multi-donor classes, suggesting that these immunogens have potential to activate such precursor cells in humans. Joyce et al. 7 showed that H5 HA immunization in human clinical trials resulted in bnAbs against group 1 and group 2 influenza viruses. Co-crystal structures with HA 75 demonstrated recognition of overlapping epitopes on the HA stem by these human classes of bnAbs using germline genes and convergent sequence motifs. One such antibody class utilized VH6-1 and DH3-3 (VH6-1+DH3-3) recognizing the HA stem and avoiding the conserved HA1 glycans of the respective group 1 and group 2 subtypes. In each case, a somatically mutated CDR H3 residue was inserted into the conserved Trp21HA2 pocket in the hydrophobic groove of HA2. Small animal models like mice and ferrets have been 80 widely used for studying vaccine responses and antibody mediated protection. However, these animal models do not recapitulate the human immune repertoire due to the lack of sequence homology with human immunoglobulin genes. Non-human primates (NHPs) are evolutionarily close to humans and can generate immune responses similar to humans, which makes them a preferred model for vaccine studies especially when focused on specific antibody lineages. Moreover, NHPs have recently been shown to elicit bnAbs 85 against influenza viruses 16 . Although NHPs lack VH genes possessing the hydrophobic CDR H2 tip as seen in the human immunoglobulin germline VH1-69, the VH gene most commonly used by group 1 HA stemrecognizing human bnAbs 17 , there are some with human resemblance, including those similar to genes contributing to the VH6-1+DH3-3 class of human multi-donor bnAbs that can facilitate HA stem recognition in monkeys 16 . 90 Here, we extend our ability to design additional group 2 stabilized HA stem trimers displayed on ferritin nanoparticles using the HA sequence of an avian H10N8 virus (H10ssF) which causes sporadic infections in humans. We found that the resulting H10ssF elicited broadly protective antibody responses against challenge with multiple heterosubtypic group 2 viruses in mice. We also explored co-immunization with the HA stem of group 1 (H1ssF) and group 2 (H10ssF) to elicit cross-group protective immunity in mice, ferrets, 95 and NHPs. Further, we isolated and characterized vaccine-elicited monoclonal antibodies for their specificity and protective efficacy. We found that a combined immunization of group 1 and group 2 HAssFs conferred not only contiguous group-specific neutralizing and protective antibody responses but also cross-group reactive bnAb responses that recognized the stem supersite in a manner reminiscent of the human multidonor VH6-1+DH3-3 class bnAbs, providing a step towards developing broadly protective influenza vaccines. 100 Design and characterization of H10 HA stabilized stem nanoparticle (H10ssF) We have previously developed a method to structurally stabilize group 2 HA stem such as H3 and H7 in native-like trimers and display on self-assembling ferritin nanoparticles (H3ssF and H7ssF, respectively) as potential immunogens for eliciting antibody responses to the highly conserved HA stem 14 . While H3ssF and 105 H7ssF induced stem-directed protective immune responses to homotypic viruses in mice, neither of them had shown to elicit heterosubtypic protective immunity that spans across multiple group 2 subtype viruses. To overcome this hurdle of conferring heterosubtypic protective immunity, we sought to improve the group 2 stem immunogen by redesigning it with different HA subtype sequences. To identify a candidate group 2 HA that has a better cross-reactive potential, we determined the conservation of primary sequences as well 110 as solvent-exposed residues among different group 2 HA stems ( Supplementary Fig. 1a ,b). We found that the H10 stem is uniquely positioned between H3 and H7 phylogenetically and possesses slightly higher sequence and solvent-exposed residue identities both to H3 and H7 than those between H3 and H7 ( Supplementary Fig. 1c,d) . We hypothesized that the H10-based group 2 stem immunogen might have a better antigenic surface to elicit broadly cross-reactive antibody responses. We employed the same design 115 principle to stabilize the H10 HA stem and generate H10ssF using A/Jiangxi-Donghu/346/2013 (H10N8) as previously described 14 . The self-assembled H10ssF was readily purified from the culture supernatant of transfected mammalian cells which gave a distinct peak around 1.2 MDa corresponding to a size of fully assembled particles on size exclusion chromatography ( Supplementary Fig. 2a) , with monomeric subunits corresponding to ~45 kDa as predicted ( Supplementary Fig. 2b ). The purified H10ssF showed 120 homogeneous and well-formed particles when analyzed by negative stain electron microscopy (nsEM) (Supplementary Fig. 2c) . A reference-free 2D class averaging of nsEM dataset resulted in particles with spherical cores of ~12 nm diameter and regularly spaced spikes of ~7-8 nm in height, consistent with the design and previously reported group 2 HAssFs 14 . Single-particle cryo-electron microscopy (cryo-EM) reconstruction of the full H10ssF particle resulted in a 4.8 Å resolution structure that revealed structural 125 elements of the ferritin core and the spikes of HA-stem trimers (Fig. 1a, Supplementary Fig. 2d-g) . Although the ferritin core could be further resolved through focused refinement, the density for the stem trimers became increasingly diffuse, suggesting their flexibility relative to the core granted by the short 3-amino acid (SGG) linker. Low-pass filtering the density map to 8 Å was able to resolve the stem domain and its angular orientation, while also suggesting the magnitude of the stem domain flexibility. Dynamic light scattering 130 (DLS) showed homogeneous particles with a radius of ~10 nm ( Supplementary Fig. 3a) . We measured the thermostability of H10ssF by differential scanning fluorometry (DSF) and found that H10ssF was equivalent or more thermally stable than other group 2 HAssFs or group 1 H1ssF 9,14 ( Supplementary Fig. 3b ). We next evaluated the antigenic integrity of H10ssF by assessing binding of cross-group, stem-specific, conformation-dependent bnAbs FI6v3 (ref. 18 ), MEDI8552 (ref. 19 ), CT149 (ref. 20 ), 315-53-1F12 (ref. 8 ), 135 group 2 stem-specific CR8020 (ref. 21 ) and 315-24-1E07 (ref. 8 ), and group 1 stem-specific CR6261 (ref. 22 ) and 315-02-1H01 (ref. 8 ) by ELISA. Analogous to H3ssF and H7ssF, H10ssF was recognized by all the stem-directed mAbs except for the group 1-specific mAbs, CR6261 and 315-02-1H01 (Fig. 1b , Supplementary Fig. 3c ). We also measured the binding kinetics of the antigen-binding fragment of antibody (Fab) of MEDI8852, CT149 and CR8020 to H10ssF by biolayer interferometry (BLI) and found that H10ssF 140 bound all three bnAbs with high affinities (KD) of 0.4-4 nM, that were equivalent or of higher affinity than the corresponding H10 HA trimer or other group 2 HAssF ( Supplementary Fig. 3d ). To evaluate the ability of H10ssF to activate B cells expressing B-cell receptors (BCRs) of the inferred UCA of human bnAbs, we measured Ca 2+ flux by flow cytometry using recombinant Ramos B cells as described previously 23,24 . We found that H10ssF but not H1ssF activated the recombinant Ramos B cells expressing BCR of 16.a.26 UCA 145 which engages group 2 HA stem (multi-donor VH1-18 Q-x-x-V class) 7,14 ( Supplementary Fig. 4a ). In contrast, B cells expressing a group 1-specific BCR were activated by H1ssF but not by H10ssF ( Supplementary Fig. 4b ). These results demonstrate that H10ssF displays conformationally and antigenically intact trimeric headless HA stem spikes that are capable of engaging and activating B cells expressing BCR of human bnAb precursors. 150 Group 2 H10ssF elicits broad heterosubtypic protective immunity in mice To assess the immunogenicity of H10ssF and compare it with other group 2 HAssF, we immunized mice with H3ssF, H7ssF, or H10ssF in the presence of adjuvant (Sigma Adjuvant System (SAS)). All three immunogens were immunogenic and elicited antibody responses that were cross-reactive to more than one 155 group 2 HA subtype although the highest antibody titers were observed against HAs matched to the immunogen subtype (Fig. 1c) . When we measured virus neutralizing activity using the HA/NA pseudotyped lentiviral reporter assay 25 , as expected, we observed serum neutralizing activity against the pseudovirus with matched HA/NA subtype ( Supplementary Fig. 5a ). There was low but detectable neutralization activity against heterosubtypic pseudoviruses in H7ssF-and H10ssF-immunized mice ( Supplementary Fig. 5a ). To 160 evaluate protective efficacy of the group 2 HAssF, immunized mice were challenged with a lethal dose of A/Philippines/2/1982 (H3N2), A/Anhui/1/2013 (H7N9) or A/Jiangxi-Donghu/346/2013 (H10N8) influenza viruses. Nearly all of the control mice (97% or 29 of 30 mice) receiving bare ferritin nanoparticles succumbed to infection and were euthanized; in contrast, mice immunized with H10ssF exhibited substantial protection against all 3 viruses tested (93% or 27 of 30 mice survived overall) (Fig. 1d) . While both H3ssF and H7ssF 165 were previously demonstrated to confer protection against homologous subtype viruses 14 , they also provided a near-complete (90-100%) protection to heterosubtypic H10N8 virus (Fig. 1d) . In contrast, H3ssF and H7ssF conferred only minimal to partial protection against heterosubtypic H7N9 and H3N2 viruses, respectively (10% and 50%, respectively) (Fig. 1d) . These results illustrate that H10ssF induces a broader protective immunity against group 2 subtype viruses than either H3ssF or H7ssF in mice. To better 170 understand the basis for this stem-directed protective immunity to group 2 viruses, we tested the specificity of both binding and neutralizing antibodies by using an HA variant which possesses an added N-linked glycan at the epicenter of the canonical stem supersite (Δstem HA) so that it blocks access of vast majority of stem-directed bnAbs 26 . Binding antibody titers of sera from H10ssF immunized mice to ∆stem H10 HA were significantly lower than to the wild-type H10 HA (p = 0.0028). Antibody titers to heterosubtypic H7 HA 175 were almost completely abrogated when the ∆stem mutation was introduced ( Supplementary Fig. 5b) , suggesting that H10ssF immunization elicited antibodies that target the canonical stem supersite surrounding the Trp21HA2 hydrophobic groove 27 and those antibodies were responsible for heterosubtypic cross-reactivity. Similarly, sera from H7ssF-immunized mice showed reduced binding to both homologous and heterologous HAs in the presence of the ∆stem mutation ( Supplementary Fig. 5b) . Importantly, the 180 serum neutralizing activity of H10ssF-immunized mice was not substantially diminished by the excess ∆stem HA protein unlike the wild-type HA which fully depleted the activity ( Supplementary Fig. 5c ). In addition, serum immunoglobulins (Igs) purified from H10ssF-immunized mice (H10ssF-Igs) reacted with H10 and H7 HA, and the binding was significantly lower to ∆stem H10 HA and nearly abolished to ∆stem H7 HA as seen in immune sera ( Supplementary Fig. 5d ). The H10ssF-Igs neutralized homologous H10N8 or heterosubtypic 185 H3N2 and H7N9 pseudoviruses ( Supplementary Fig. 5d ). To confirm that the heterosubtypic group 2 protection is antibody-mediated, H10ssF-Igs were passively administered to naïve mice prior to infecting them with a lethal dose of H7N9 virus. Mice receiving the H10ssF-Igs were fully protected from the virus with no measurable weight loss (Fig. 1e) , while all mice receiving Igs purified from naïve mice succumbed to infection. This result shows that the heterosubtypic group 2 protection can be achieved by stem-directed 190 antibodies elicited by H10ssF. Co-immunization of group 1 and group 2 HAssF confers cross-group heterosubtypic immunity. To achieve the goal of eliciting protective immune responses to influenza A viruses carrying either group 1 and group 2 subtype HAs, we evaluated a cocktail vaccine approach consisting of H1ssF and H10ssF. Groups of mice, ferrets and cynomolgus macaques were immunized with a cocktail of H1ssF and H10ssF (termed herein H1+10ssF) with a squalene oil-in-water emulsion adjuvant (AddaVax®). Immunization of 220 H1+10ssF elicited HA-binding and neutralizing antibody responses to several group 1 and group 2 subtype viruses in mice ( Fig. 2a,b) , ferrets ( Fig. 2c ) and nonhuman primates (NHPs) (Fig. 2d) . The levels of antibody responses to group 1 viruses were comparable to that induced by H1ssF alone (Fig. 2a-c) , and likewise, the responses to group 2 viruses were comparable to that induced by H10ssF alone (Fig. 2a-c) . These findings confirm that the co-immunization of group 1 and group 2 HAssF does not cause antigenic 225 competition between the two HAssF immunogens. Importantly, co-immunization also conferred substantial protection in immunized mice from heterosubtypic H5N1 and H3N2 lethal virus challenges ( Supplementary Fig. 6a ,b). Although heterosubtypic virus neutralizing antibody responses in mice and ferrets could be measured by pseudotyped lentiviral neutralization assays, serum neutralizing activity in immunized NHPs were also readily detectable in influenza reporter virus-based microneutralization assays (Fig. 2d ) 28 . Mouse 230 and ferret immune sera neutralized all 5 pseudotyped viruses that represent group 1 and group 2 human influenza viruses, whereas NHP immune sera did not show detectable neutralization against the H3N2 virus ( Fig. 2b-d) . These results suggest that immunizations with H1+10ssF can elicit broadly neutralizing serum antibody responses that are capable of neutralizing multiple group 1 and group 2 subtype viruses although the breadth may be more limited in NHPs. To better understand the basis for cross-reactive antibody responses observed in NHPs immunized with H1+10ssF, we assessed the B cell responses to multiple HAs in peripheral blood mononuclear cells 255 (PBMCs) by flow cytometry. Two weeks after the second immunization (week 6), B cells binding to homologous H1 MI15 HA and H10 JD13 HA were readily detectable (Fig. 3a, Supplementary Fig. 7) . Frequencies of IgG + B cells recognizing homologous H1 and H10 HA were substantially increased after the third immunization ( Fig. 3b ). At week 12, a large fraction (~50%) of the H1 + IgG + B cells showed crossreactivity to H5 VN04 HA and likewise, approximately half of the H10 + B cells bound H7 AN13 HA; whereas, 260 cross-reactivity between H10 and H3 HK14 HAs was markedly lower than H7 (Fig. 3c) . B cells that recognize both group 1 (H1) and group 2 (H10) HAs were rare yet detectable (Fig. 3a) . We next assessed the kinetics for the development of cross-reactive B cell responses in the animal (M08145, circle) which had the highest cross-group HA-reactive B cells. The frequency of B cells recognizing homologous HAs (i.e., H1 and H10) were low but detectable as early as one week after the first H1+10ssF immunization (week 1) (Fig. 3d) . 265 Frequencies of both homologous H1 + and H10 + B cells were remarkably increased after the second and the third immunizations (week 5 and week 11, respectively). A disproportional increase of H5 + B cells compared to H1 + only B cells was observed after the second and the third immunization, indicating that selective induction of cross-reactive B cells occurred after each H1+10ssF booster (Fig. 3d) . Notably, B cells crossreacting with both H1 and H10 (cross-group) emerged after the second immunization, while the relative 270 frequency of these cells were substantially enriched after the third immunization (Fig. 3e ). These results demonstrate that a cocktail of H1ssF and H10ssF is capable of inducing a diverse repertoire of crossreactive HA-specific B cells including some that cross-react with both group 1 and group 2 HAs. Among the mAbs derived from cross-group HA-specific B cells, we found an antibody clone 789-203-3C12 that bound multiple subtype HAs and neutralized a wide range of influenza viruses in the reporter-based 290 microneutralization assays (Fig. 4a,b) . Binding affinities of the 789-203-3C12 Fab to various subtypes of HA varied ranging from 6.6 to 534 nM (Fig. 4a) . Although the mAb 789-203-3C12 did not show detectable binding to H3 HA nor neutralized H3N2 viruses, it bound and neutralized multiple group 1 and group 2 HA subtype viruses (Fig. 4b) . 789-203-3C12 was highly protective against both group 1 (A/California/04/2009 (H1N1) and H5N1 VN04) and group 2 (H7N9 AN13 and H10N8 JD13) virus infections when the antibody 295 was given prophylactically to naïve mice (Fig. 4c) . These results establish that the co-immunization of H1+10ssF can induce robust B cell responses that are cross-reactive to heterosubtypic HAs not only within either group 1 or group 2, but also across the two HA groups. In addition, the mAb 789-203-3C12 isolated from H1+10ssF-immunized NHP showed cross-group neutralizing activity as well as protective efficacy to multiple group 1 and group 2 subtype influenza viruses. To study the molecular basis for broad cross-group neutralization, we characterized immunogenetic composition of 789-203-3C12. The VH region of 789-203-3C12 is highly similar to the M. fascicularis IGHV4S14 gene (96.2%), suggesting it acquired a pair of Cys substitutions within CDR H1 and H2 regions 305 (Tyr33Cys and Tyr52Cys, respectively) alongside a few other substitutions in its framework regions during somatic hypermutation (SHM) (Fig. 4d) . Among the sequences of single-cell sorted B cells, we found a somatic variant heavy chain sequence clonally related to 789-203-3C12 which did not possess the double Cys substitutions in its CDR H1 and H2 loops (Fig. 4d) . Interestingly, when the recombinant antibody was produced using the somatic variant heavy chain paired with 789-203-3C12 light chain, the resultant mAb 310 had comparable neutralizing activity against H1N1 MI15 virus (Fig. 4b) ; however, this somatic variant mAb had a much reduced neutralizing activity against heterologous pre-pandemic H1N1 (A/New Caledonia/20/1999) and heterosubtypic H5N1 VN04 viruses. Moreover, its neutralizing activity against the group 1 H2N2 or the group 2 subtype viruses was completely abolished (Fig. 4b) . To test whether the Cys substitutions were critical for its binding and neutralization breadth and potency, we generated two variant To understand the structural basis for HA recognition by 789-203-3C12, we determined the structure of 789-203-3C12 Fab in complex with recombinant stabilized HA trimer 29 of H1N1 virus (A/Solomon Islands/3/2006, SI06) to 3.85 Å resolution by single-particle cryo-EM (Fig. 5a, Supplementary Fig. 8 ). While 60,632 particles 345 showed C3 symmetry, the dataset for the HA-Fab complex structure was collected based on the 116,041 particles which showed C1 symmetry (Supplementary Table 1 ). 789-203-3C12 bound to the canonical HA stem supersite, with HA1 and HA2 subunits providing 15% (153 Å 2 ) and 85% (837 Å 2 ), respectively, of a total buried surface area (BSA) of 990 Å 2 (Supplementary Table 2 ). The heavy chain dominated the binding interface and contributed 75% of the 1,066.32 Å 2 paratope surface (Supplementary Table 2 ). In the CDR 350 H3, Arg100f formed a salt bridge with the HA residue Asp19HA2, and Val100c interacted with the Val18HA2 through hydrophobic contacts (Fig. 5b, Supplementary Table 3 ). Phe100 at the tip of the CDR H3 bound in a hydrophobic groove formed by residues Trp21HA2, Ile45HA2, and Ile48HA2 (Fig. 5b) . Overall, CDR H3 contributed ~51% of the total paratope surface (Supplementary Tables 4,5) . As expected, Cys33 and Cys52 formed an intra-chain disulfide bond, with well-resolved electron density ( Supplementary Fig. 8e) , linking 355 CDR H1 and CDR H2 (Fig. 5b) . This CDR H1-H2 disulfide bond provided perfect shape complementarity to accommodate the loop consisting of the HA2 residues 16-21, and helped orient the Val18HA2 and Asp19HA2 to interact with CDR H3 (Fig. 5b ). In addition, CDR H2 residues Gly55 and Lys64 formed hydrogen bonds and salt bridges with Tyr34HA2 and Asp146HA2, respectively (Fig. 5b, Supplementary Table 4,5) . The light chain residues Arg50, Ser91, and Thr92 formed hydrogen bonds with Gln42HA2, Asn46HA2, and Thr49HA2 360 (Fig. 5b, Supplementary Tables 6,7) . We noted that the macaque-derived 789-203-3C12 recognized the HA stem similar to the convergent VH6-1+DH3-3 class of human bnAbs 7 . One such human VH6-1+DH3-3 class antibody, 56.a.09 (PDB 5K9K), shared a very similar approach to the HA stem, where the heavy and light chains were superimposable with nearly identical orientations (Fig. 5c) . The epitopes for 789-203-3C12 and 56.a.09 showed a high degree of 365 overlap, sharing 21 residues (Fig. 5d) . Although the structures of CDR H1, H2 and CDR L1, L2, and L3 are substantially different between 789-203-3C12 and 56.a.09, the CDR H3 of both antibodies contained the conserved Ile-Phe-Gly-Val/Ile (Ψ-F-G-Ψ) motif, enabling both antibodies to interact with HA in a similar fashion (Fig. 5e,f) . Additionally, nsEM analyses of the 789-203-3C12 Fab in complex with H10 HA (A/Jiangxi-Donghu/346/2013) confirmed that the Fab bound the group 2 HA stem in a manner analogous to human 370 VH6-1+DH3-3 class bnAbs (Fig. 5g) . Structures of group 2 HA-Fab complex (MEDI8852-H7 HA (PDB 5JW3) and 56.a.09-H3 HA (PDB 5K9K) fit snugly into the reconstructed nsEM density of 789-203-3C12-H10 complex ( Supplementary Fig. 9 ), further highlighting the similarity between macaque and human crossgroup bnAbs. While the conserved Ile-Phe-Gly-Val/Ile motif in the VH6-1+DH3-3 class bnAbs is entirely encoded by the human IGHD3-3 gene, this same motif was completely conserved in the CDR H3 of 789-375 203-3C12 (Fig. 5f ). Due to the lack of complete immunoglobulin loci of cynomolgus macaque genome in public databases, we were unable to correctly assign the Ighd gene used by 789-203-3C12. However, we found that the nucleotide sequence corresponding to the D segment within the M. fascicularis (cynomolgus macaque) genome (GCA_011100615.1) was identical to the DH3-3 gene of M. mulatta (rhesus macaque) (GenBank MF989451.1). It is also highly homologous to the human DH3-3 gene, and encodes the core "Ile-380 Phe-Gly-Val" motif (Fig. 5h) . These facts suggest that the corresponding DH gene (putative Ighd3-3) is also present in the macaque genomes and is utilized by influenza HA stem-directed bnAbs. The ongoing global SARS-CoV-2 pandemic underscores the difficult public health challenges encountered 405 when fighting against highly contagious respiratory pathogens. Vaccines remain the most effective countermeasure to slow down transmission as demonstrated by the highly efficacious vaccines against SARS-CoV-2. Even though the vaccines are partially protective, if they were deployed early or prior to the pandemic, they could have a considerable positive impact on the epidemic curve 30 . This is particularly relevant to influenza as it is not possible to accurately predict the next pandemic virus with the available 410 technologies and research tools. Therefore, the development of vaccines for influenza pandemic preparedness that are effective against unknown pandemic viruses and their deployment immediately after a new virus emerges would be immensely valuable for maintaining global public health. Headless HA stem immunogens could also be combined with conventional split vaccines or with full-length HA immunogens to improve the breadth of immunity and could reduce the need for yearly vaccination. Alternatively, a vaccine 415 that induces broad immunity against group 1 and 2 influenza A viruses, could be stockpiled and available for deployment during the early stages of a pandemic before strain-matched vaccines can be made available. Our study demonstrated the feasibility of such a vaccine approach using a cocktail of the group 1 and group 2 headless HA stem-nanoparticles 9,14 and showed that it could elicit broadly neutralizing and protective immune responses against a wide range of influenza A viruses in three different animal models. 420 Markedly, this cocktail vaccine approach induced not only within-group (group 1 or group 2) cross-reactive antibodies but also the cross-group bnAbs in NHPs. To the best of our knowledge, this is the first study reporting the vaccine-elicitation and isolation of cross-group bnAbs resembling a public human bnAb clonotype in NHPs, providing a key step to the development of vaccines that elicit bnAbs in humans. To date, such cross-group bnAbs induced by infections and/or vaccinations in humans are rarely 425 found 7, 8, 18, 19, 31, 32 . For more than a century, small animal models have been indispensable to gain insights on fundamental biological processes and study immunological mechanisms. These animal models have been widely used in preclinical studies for evaluating vaccine immunogenicity; however, results obtained from these models do not always recapitulate complex immune responses in humans. For example, in humans, the 430 predominant bnAb responses to group 1 HA stem are largely constrained by the usage of VH1-69 genes which do not exist in nonhuman animal species 33,34 . To better address this issue, transgenic animals that carry human immune receptor genes have been developed and utilized to reproduce human-like immune responses [35] [36] [37] [38] . Despite the advances in the development of a variety of humanized transgenic and transchromosomic mice over the last few decades, it is still exceedingly difficult to model the complexity of 435 human immune responses. NHPs and in particular macaques are the preferred animal species for vaccine evaluation due to their evolutionary proximity to humans. While NHPs do not possess the human VH1-69 gene which is by far the most prevalent gene utilized for group 1 HA stem-directed bnAbs, they use a different set of VH genes (i.e., VH3S5 and VH3S25) to target the same stem epitope 16 . Analogous to humans, these group 1 HA stem-directed antibodies were highly dominant and genetically constrained public 440 clonotypes in NHPs. In addition to the group 1 HA stem-directed antibodies, NHPs have been shown to generate group 2 HA stem-directed antibodies following H3 stem-nanoparticle immunizations 16 . Noteworthily, the NHP antibodies to the group 2 HA stem target the membrane proximal epitope similar to the human group 2 HA stem-directed antibodies, such as CR8020 and CR8043 (refs. 21, 39 ). Despite the fact that NHPs were capable of generating human-like bnAb responses to either group 1 or group 2 HA stem 445 following infection or vaccination 16, [40] [41] [42] , there are no bnAbs that broadly neutralize both group 1 and group 2 influenza viruses reported to date. In the present study, we identified the NHP bnAb 789-203-3C12 as the first example of such cross-group bnAbs. Although the bnAb 789-203-3C12 was isolated from a cynomolgus macaque, the antibody was surprisingly similar to the human VH6-1+DH3-3 class of bnAbs 7, 19 . The canonical CDR H3 motif of this class of bnAbs is 450 entirely encoded by the DH3-3 gene in humans. We found the putative homolog of human DH3-3 gene in both rhesus and cynomolgus macaques' genomes that were nearly identical to the human DH3-3. While it is likely that this DH gene has been conserved in those macaque species for completely irrelevant reasons, it is astounding to observe the convergent solution to recognize the influenza HA stem between humans and macaques by utilizing this gene out of many DH genes with a particular reading frame. It is unclear at 455 the moment whether or not the VH gene (VH4S14) poses an immunogenetic bottleneck in macaques like the human VH6-1 gene does for the VH6-1+DH3-3 public clonotype. We also have limited understanding on why bnAb 789-203-3C12 does not neutralize H3N2 viruses and if this limitation is common amongst NHP crossgroup bnAbs. Further antibody discovery efforts would be needed to address these questions and leverage the NHP model for studying the germline gene-endowed immunological processes in response to the HA 460 stem. Although we and others have shown that the HA stem-directed broadly cross-reactive antibody responses can be elicited in multiple animal models through active immunization of designed immunogens 9,14,15,43-45 , the potential impacts of preexisting influenza immunity on vaccine-elicitation of the stem-directed antibody responses have not been rigorously studied. A recent natural history study uncovered a substantial impact 465 of early life influenza exposures on protective immunity against heterosubtypic influenza virus infections in humans 46 . The observed protective immunity appeared to be HA group-specific and determined by the subtype of influenza virus that the individual was first exposed to in their early childhood (H1N1, H2N2, or H3N2). This "immunological imprint" introduces birth year-dependent bias in immune repertoire and may influence group preference of the vaccine-induced immunity, posing another layer of difficulty for achieving 470 universal influenza immunity in humans 47 . Whether a designed vaccine can override and reprogram the imprinted group-biased immunity in humans remains to be determined, although there are vaccine candidates in advanced clinical trials that show some promise in phase 1 human clinical trials by eliciting the HA stem-directed antibody responses in adults with preexisting influenza immunity 48-50 . In addition, the building block of our stem-nanoparticles is encoded by a single gene and its assembly is precise and 475 efficient, making it a candidate for genetic vaccine delivery approaches such as mRNA and recombinant viral vectors. These vaccine modalities have been pivotal for combating the ongoing SARS-CoV-2 pandemic and are anticipated to play major roles in other vaccines onward. These modalities along with innovative new adjuvants would offer not only manufacturing options and dose sparing but also different immunological properties including durability and cellular immunity. The present study provides a proof-of-concept for the 480 vaccine-elicitation of broad cross-group protective immunity and would foster future studies addressing outstanding challenges such as preexisting immunity and durability. Furthermore, both group 1 HA stemand group 2 HA stem-nanoparticles reported herein have entered phase 1 clinical trials (NCT03814720 and NCT04579250, respectively) to evaluate safety and immunogenicity in humans. Results from these trials would inform the feasibility of the HA stem-based vaccine strategies for eliciting bnAb responses and Structure based immunogen design. The complete sequence for A/Jiangxi-Donghu/346/2013 (H10N8) including the signal sequence, was obtained from the GISAID accession number EPI497477. The crystal structure of A/Jiangxi-Donghu/346/2013 (H10N8) HA (PDB ID 4QY0) was used as a template for modeling 600 using the "C" version of HAssF as previously described 14 . Loops were modeled with the program LOOPY 51 , superpositions were performed using UCSF Chimera 52 or LSQMAN 53 , energy minimization was performed using RELAX 54 and the free energy changes from point mutations were calculated using the program DDG_MONOMER 55 from the ROSETTA suite. PyMOL (Schrodinger, LLC) and UCSF Chimera 52 were used for detailed visualization of structures and structural figure generation. Expression and purification of immunogens, antibodies and probes. The H3ssF, H7ssF and H10ssF sequences each incorporated the "C" version of group 2 HAssF as described previously 14 . The HAssF nanoparticles, H3ssF, H7ssF, H10ssF and H1ssF, monoclonal antibodies (mAbs) FI6v3 (ref. 18 ), CT149 20 , CR8020 (ref. 21 plates were incubated with 4-fold serially diluted mAbs with dilution series starting at 10 ng ml -1 or immune sera dilutions starting at 1:50. Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (Southern Biotech) were added and incubated for 1 hr followed by a colorimetric detection assay utilizing 3,3′,5′,5-tetramethylbenzidine (TMB) substrate (KPL). The colorimetric reaction was stopped by addition of 1 M H2SO4 and the absorbance recorded at 450 nm (OD450). Serum endpoint titers were recorded as serum 660 dilution resulting in 4-fold increase in OD450 value above the background level. Biolayer interferometry binding assays. The biolayer interferometry binding assays were done as previously described 14, 57 . All biosensors were hydrated in PBS prior to use. CR9114 (ref. 31 ) was used at 10 µg ml -1 in PBS containing 1% bovine serum albumin (PBS-BSA) to coat AHC biosensors (fortéBio) to capture H10ssF. The CR9114-coated biosensors were dipped in H10ssF (10 µg ml -1 in PBS-BSA). After equilibrated 665 for 60 s in PBS-BSA, the biosensors were then dipped in a 2-fold dilution series of MEDI8852, CT149, or CR8020 Fab for 300 s, followed by incubation in PBS-BSA for 300 s to allow for dissociation. For 789-203-3C12, recombinant HAs (10 µg ml -1 ) were immobilized on HIS1K biosensors through hexa-histidine tag. After briefly equilibration in PBS-BSA, the biosensors were dipped in a 2-fold dilution series of 789-203-3C12 Fab for 300 s followed by dissociation in PBS-BSA for 300 s. All assay steps were performed at 30ºC 670 with agitation set at 1,000 rpm in the Octet HTX instrument (fortéBio). Correction to subtract non-specific baseline drift was carried out by subtracting the measurements recorded for a bare sensor. Data analysis and curve fitting were carried out using Octet analysis software (v9). Experimental data were fitted with the binding equations describing a 1:1 interaction. Global analyses of the complete data sets assuming binding was reversible (full dissociation) were carried out using nonlinear least-squares fitting allowing a single set 675 of binding parameters to be obtained simultaneously for all concentrations used in each experiment. Negative stain electron microscopy analysis. Purified H3ssF, H7ssF, and H10ssF were diluted to 0.02 mg ml -1 with buffer containing 10 mM HEPES, pH 7.0, and 150 mM NaCl and adsorbed onto glowdischarged carbon-coated copper mesh grids for 15 s. The grids were washed with the buffer and stained with 0.7% uranyl formate. Images were obtained at a magnification of 50,000 semi-automatically on an FEI 680 Tecnai T20 transmission electron microscope (TEM) operated at 200 kV, equipped with a 2,048-by 2,048pixel Eagle charge-coupled-device (CCD) camera using SerialEM 58 . The pixel size was 0.44 nm and particles were picked automatically using software developed in-house. Reference-free 2D classification was performed using SPIDER 59 and Relion 1.4 (ref. 60 ). For 3D reconstruction of the H10 JD13 HA trimer in complex with 789-203-3C12 Fab, the purified components were mixed at a molar ratio of 1.1 Fab to 1 HA 685 protomer, briefly incubated on ice, and negatively stained as described above. A dataset containing 144 micrographs was collected using the same TEM at a nominal magnification of 100,00x, corresponding to a pixel size of 0.22 nm, and 4746 particle images were selected using e2boxer from EMAN2 (ref. 61 ) and extracted into 128-by 128-pixel boxes. After 2D classification in Relion 3.0, selected 2D class averages were used to generate an ab-initio 3D model in EMAN2. This was followed by 3D classification and 3D auto-690 refinement in Relion with imposed C3 symmetry. The final dataset contained 1173 particles, and the resolution at the Fourier shell correlation threshold of 0.5 was 24.8 Å. Cryo-EM structure of H10ssF. Purified H10ssF was applied to glow discharged Quantifoil R 2/1 300 mesh grids (Ted Pella, Redding) at a concentration of 1 mg ml -1 . Using a Leica EM GP plunge freezer (Leica Microsystems), the grid was blotted for 1 s at 37°C and 68% humidity, then plunge-frozen in liquid ethane. 695 Plunged grids were loaded into a Polara electron microscope (ThermoFisher Scientific) operated at 300 keV, equipped with a Falcon 2 direct electron detector (ThermoFisher Scientific), and EPU data acquisition software (ThermoFisher Scientific). Total of 4,027 micrographs, dose fractionated into 7 frames, were collected at a magnification of 78,000 ×, with 1.43 Å 2 pixel -1 and a total dose of 47 epixel -1 . Movie frames were aligned using MotionCor2 (ref. 62 ), and the contrast transfer function for each micrograph was fitted 700 using CTFFIND4 (ref. 63 ). Total of 262 particles were manually picked to generate class averages with RELION2 (ref. 64 ), which were used for autopicking of 693,018 particles by Gautomatch v0.56 (https://www2.mrc-lmb.cam.ac.uk/download/gautomatch-056/). Further curation and alignment of particle sets was performed with RELION2. Particles were 2D classified in batches of 30,000-60,000, culling overlapping particles and false-positive particle picks from the analysis. For 3D analysis, an initial model of 705 a solid sphere of diameter 220 Å was used, combined with an outer spherical mask of diameter 325 Å. Iterative 3D refinement of 118,473 particles against the model using "gold-standard" refinement of 2 independent half-maps as implemented in RELION2 generated a map at a resolution of 4.8 Å, using a 0.143 FSC cutoff and post-processed with an ad-hoc B-factor of -300. While antigenic spikes on H10ssF were observed during initial low-resolution refinement, their density became unresolved as the refined resolution 710 improved. The location of the antigenic spikes could again be visualized by low-pass filtering the final map back to 8 Å resolution. Cryo-EM structure of Fab-HA complex. The sample for cryo-EM analysis of 789-203-3C12 Fab in complex with stabilized HA trimer of H1N1 virus (A/Solomon Islands/3/2006, SI06) was produced by mixing the Fab and HA trimer in a 6:1 molar ratio, with a final trimer concentration of 0.2 mg ml -1 , followed by incubation on 715 ice for 1 hr. The protein complex was purified by a Superdex 200 16/60 column in a buffer containing 5 mM HEPES pH 7.5 (Life Technologies) and 150 mM NaCl (Quality Biological, Inc.). To prevent aggregation during vitrification, 0.005% (w/v) n-dodecyl β-D-maltoside was added to the sample prior to plunge freezing. Cryo-EM grids were prepared by applying 2 ml of sample to a freshly glow-discharged carbon-coated copper grid (CF 1.2/1.3 300 mesh); the sample was vitrified in liquid ethane using a Vitrobot Mark IV with a wait 720 time of 30 s and a blot time of 3 s. Cryo-EM data were collected using the Leginon software 65 installed on a Titan Krios electron microscope operating at 300 kV, equipped with a Gatan K3-BioQuantum direct detection device. The total dose was fractionated for 3 s over 60 raw frames. Motion correction, CTF estimation, particle extraction, 2D classification, ab initio model generation, 3D refinements and local resolution estimation for all datasets were carried out in cryoSPARC 2.15 (ref. 66 ). The final 3D reconstruction 725 was obtained using non-uniform refinement with C1 symmetry. HA trimer density was modeled using PDB entry 6FYT 67 , as initial template. The heavy chain variable region of 789-203-3C12 Fab was modeled using PDB entry 4FQQ 68 while the light chain variable region was modeled using PDB entry 5OD8 (ref. 69 ). Automated and manual model building were iteratively performed using real space refinement in Phenix 70 and Coot 71 , respectively. Half maps were provided to the Resolve Cryo-EM tool in Phenix to support manual 730 model building. Geometry validation and structure quality assessment were performed using EMRinger 72 and Molprobity 72,73 . Map-fitting cross correlation (Fit-in-Map tool) and figures preparation were carried out using PyMOL and UCSF Chimera 52 and ChimeraX 52,74 . A summary of the cryo-EM data collection, reconstruction and refinement statistics is shown in Supplementary Table 1 . Differential scanning fluorimetry. Thermal unfolding of purified HAssF in PBS was measured by nano 735 differential scanning fluorometry (nDSF) using Prometheus NT.48 instrument (NanoTemper technologies). Thermal unfolding curves are plotted slope (Δ(F350 nm/F330 nm)/ΔT) against temperature (ºC) generated from fluorescence measurements at 350 and 330 nm. Thermal transition midpoint temperature (Tm) was calculated from the curves and reported. Dynamic light scattering. Dynamic light scattering (DLS) measurements were performed using a DynaPro 740 Plate Reader II (Wyatt Technology). Protein samples of 0.5 mg ml -1 were centrifuged at 13,000 rpm in a tabletop refrigerated microfuge at 4°C for 45 minutes prior to aliquoting 30 µl of each into clear flat bottom 384-well plate (Corning). Measurements for each sample were taken at 25°C in the laser auto-attenuation mode and a wavelength of 830 nm from a total of 10 data acquisitions. DLS data was processed using Dynamics 7.8.2 software using a Rayleigh spheres model. Influenza pseudovirus and microneutralization assays. Pseudoviruses used for the assay were based on lentivirus vectors encoding the luciferase gene and expressing influenza HA and NA as previously described 26 . Replication-restricted reporter influenza viruses used in this study were previously described 28 . Animal serum was treated with receptor-destroying enzyme, RDE (Denka Seiken) for 37°C, 16 h followed by RDE denaturation at 56°C for 1 h. For pseudovirus neutralization assay, a four-fold serial dilution of 750 Supplementary Fig. 1-9 Supplementary table 1-7 Influenza Vaccine Effectiveness: New Insights and Challenges Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide Hemagglutinin-Mediated Membrane Fusion: A Biophysical Perspective Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses Preferential induction of cross-group influenza A hemagglutinin stem-specific 505 memory B cells after H7N9 immunization in humans Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines Influenza virus vaccine based on the conserved hemagglutinin stalk domain Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with 525 IGHV utilization shifts and varies by ethnicity A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus A highly conserved neutralizing epitope on group 2 influenza A viruses mouse sera starting at 1:40 were mixed with either H3N2 (A/Hong Kong/1/1968, HK68) After 2 h fresh Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine 755 serum (FBS), 2 mM glutamine, and 1% penicillin-streptomycin was added. Cells were lysed at 72 h, and luciferase assay (Promega) was performed according to manufacturer's protocol. Luciferase activity was measured as RLU at 570 nm on a SpectramaxL (Molecular Devices). For influenza neutralization assay, a four-fold serial dilution starting at 1:40 (serum samples) or 25 µg ml -1 (mAbs) were mixed with one of these replication JD13) for 60 min at RT. The serum-virus mixtures were added to previously plated MDCK-SIAT1 cells stable expressing influenza PB1 gene (3,000 cells well -1 in a 384-well plate with transparent bottom) in quadruplicate. Plates were scanned at 18-22 h post infection and fluorescence foci were counted using Celigo Image Cytometer (Nexcelom) Target 1 protocol was used to detect and count fluorescent foci 28 . IC50 titers were calculated considering uninfected cells as 100% and cells transduced with only virus as 0% neutralization Ramos cells expressing inferred unmutated common ancestor (UCA) sequence of bnAbs as IgM on their surface were utilized. These cells were stained 770 with fura red (ThermoFisher Scientific) in serum free medium at room-temperature for 30 min. Cells were washed and resuspended in serum free medium, incubated at 37°C for 5 min followed by acquisition on a FACSymphony interfaced to the FACSDiva software (BD Biosciences). Cells were acquired without the nanoparticle (baseline) followed by acquisition in presence of the nanoparticle and acquisition for 180 s. The anti-IgM was used as positive control to assess maximal calcium flux induction measured as change in 775 emission by bound versus unbound fura red to calcium over time. The inferred UCA for 01 Cryopreserved peripheral blood mononuclear cells (PBMCs) were used. A panel of antibodies were used to stain the cells and gate for particular cell subsets Antibodies to CD16 (clone 3G8), CD3 (clone SP34-2), CD56 (clone B159), IgM (clone G20-127) H10 JD13) full-length ectodomain HA probes with the sialic acid-binding site mutation (Y98F) were prepared as previously described 75 . HA probes were conjugated with fluorescently-labeled 785 streptavidin through biotin ligated to the Avi-tag on each probe. The cells were stained with a panel of antibodies to the surface markers and HA-streptavidin probes. The viability dye 7AAD was used for excluding dead cells. The samples were analyzed on a FACS Aria II (BD Biosciences) and single-cell sorted into 96-well plates. Index sorting was applied to identify specificity of individual cells for multiple HA probes. Data analysis and subsequent flowplots were generated following cell sorting using FlowJo (v10). PCR 790 amplification of immunoglobulin heavy and light chain genes and cloning into expression vectors were performed as previously described 76 Specific details of statistical analysis are indicated in the figure legends and the Results section. P-values less than or equal 795 to 0.05 were considered significant. Normality tests were conducted on all data to determine the appropriate statistical test Further information on research design is available in the Nature Research Reporting Summary linked to this article Cryo-EM structures have been deposited in the Electron Microscopy Data Bank (EMDB) under accession code EMD-26044 (H10ssF) and EMD-22302 (789-203-3C12 Fab-HA complex); and in the Protein Data Bank (PDB) under accession code 6XSK (789-203-3C12 Fab-HA complex) UCSF Chimera--a visualization system for exploratory research and analysis Use of non-crystallographic symmetry in protein structure refinement A Pareto-optimal refinement method for protein design scaffolds Role of conformational sampling in computing mutationinduced changes in protein structure and stability Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses Automated electron microscope tomography using robust prediction of specimen movements SPIDER image processing for single-particle reconstruction of biological 825 macromolecules from electron micrographs RELION: implementation of a Bayesian approach to cryo-EM structure determination EMAN2: an extensible image processing suite for electron microscopy MotionCor2: anisotropic correction of beam-induced motion for improved cryoelectron microscopy CTFFIND4: Fast and accurate defocus estimation from electron micrographs Accelerated cryo-EM structure 835 determination with parallelisation using GPUs in RELION-2 Automated molecular microscopy: the new Leginon system cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein Antibodies Recent developments in the PHENIX software for automated crystallographic structure determination Coot: model-building tools for molecular graphics EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy MolProbity: structure validation and all-atom contact analysis for nucleic acids and their complexes Structure visualization for researchers, educators, and developers Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stemdirected antibodies from multiple Ig heavy-chain lineages Isolation of antibody V(D)J 860 sequences from single cell sorted rhesus macaque B cells MUSCLE: multiple sequence alignment with high accuracy and high throughput Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution Bioqual) for help with influenza challenge studies ) and the Office of Cyber Infrastructure and Computational Biology (OCICB) High Performance Computing (HPC) cluster at the NIAID, NIH. Funding: This work was supported 875 in part by Intramural Research Program of the Vaccine Research Center, NIAID, NIH; Intramural Research Program of Division of Intramural Research, NIAID, NIH; federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract number HHSN261200800001E, and by Leidos Biomedical Research, Inc. L.S. and G.C. were supported by a Bill and Melinda Gates Foundation Universal Flu Grand Challenge Award. The content is solely the 880 responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health The authors thank R. Woodward, D. Scorpio, J.